Tag: expenses

The Board of UAB “Ignitis”, a subsidiary directly controlled by Ignitis Group, a leading integrated energy group in the Baltic region (hereinafter – the Group), has approved the candidacy of Andrius Kavaliauskas for the position of CEO of UAB “Ignitis”. Andrius Kavaliauskas, the current Head of B2C at the company, will replace the company's CEO Artūras Bortkevičius, whose term of office expires on 9 July 2026. The final decision on the appointment of Andrius Kavaliauskas to the position of CEO of UAB “Ignitis” is planned to be made by 9 July 2026, following the completion of the mandatory impeccable reputation verification procedure.

YieldMax ETFs Announces Distributions on MSST, NVIT, and TEST

New class action for Regencell (RGC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/23/2026

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

New class action for Calix (CALX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/27/2026

New class action for SES AI (SES) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/26/2026

New class action for Lucid (LCID) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/28/2026

New class action for GeneDx (WGS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/3/2026

Tradr ETFs will ring Cboe's Opening Bell on June 15 to celebrate the launch of SPCM and SPCG, ETFs providing 200% leveraged long and...

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

Defiance ETFs Announces Temporary Trading Halt of the Defiance Daily 2X Space ETF (SPCL) on Cboe BZX Exchange, Inc.